Within the hospital acquired infection control market, Consumables held a 49.69% share in 2025, making it the leading type segment. This position is sustained by the routine and recurring use of products such as disinfectants, sterilization supplies, protective items, and other infection prevention materials that hospitals must replenish continuously as part of daily clinical operations. Demand remains closely tied to standard infection control protocols, patient throughput, and compliance requirements, which gives Consumables a stable volume base that service-based alternatives do not match at the same scale.

Services are emerging as the fastest-growing type segment in the hospital acquired infection control market as healthcare providers place greater emphasis on outsourced sterilization support, infection surveillance, training, and compliance management. Growth is being underpinned by the practical need for specialized expertise and standardized execution across increasingly complex care environments, especially where healthcare facilities seek to improve infection outcomes without expanding internal operational burdens. Compared with consumables, services are gaining momentum because they address ongoing process management and institutional capability gaps rather than product replenishment alone.

End Use Segment Analysis: Hospitals and Intensive Care Units (ICUs) (Largest Segment) vs Ambulatory Surgical and Diagnostic Centres (Fastest-Growing Segment)

Hospitals and Intensive Care Units (ICUs) accounted for the largest share of the hospital acquired infection control market in 2025. Their leadership reflects the concentration of high-risk patients, invasive procedures, extended lengths of stay, and continuous exposure to infection-sensitive environments, all of which require strict and sustained infection prevention practices. The intensity of care delivery in these settings keeps consumption of infection control products and protocols consistently high, supporting their dominant share across end use categories.

Ambulatory Surgical and Diagnostic Centres represent the fastest-growing end use segment in the hospital acquired infection control market, driven by the rising need to maintain rigorous infection prevention standards in lower-stay, high-throughput care settings. As more procedures and diagnostic interventions are handled outside traditional inpatient environments, these centres are strengthening sterilization, disinfection, and patient safety processes to align with clinical expectations and regulatory requirements. Their growth is outpacing hospitals because infection control investment is expanding from a smaller base while operational volumes in outpatient settings continue to increase.